Literature DB >> 23429363

How molecular testing can help (and hurt) in the workup of gliomas.

Kenneth Clark1, Zoya Voronovich, Craig Horbinski.   

Abstract

Advances in genetics research have greatly expanded our ability to accurately diagnose gliomas and provide more useful prognostic information. Herein specific examples are used to show how high-yield targets such as EGFR, 1p/19q, IDH1/2, MGMT, and BRAF can expand the power of the surgical neuropathologist. To avoid errors, however, the significance and controversies associated with each test must be thoroughly understood.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23429363      PMCID： PMC4477533          DOI： 10.1309/AJCPFO8IIDNBIJ8Y

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  78 in total

1.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

Authors:  Robert B Jenkins; Hilary Blair; Karla V Ballman; Caterina Giannini; Robert M Arusell; Mark Law; Heather Flynn; Sandra Passe; Sara Felten; Paul D Brown; Edward G Shaw; Jan C Buckner
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

2.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors:  Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

3.  Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.

Authors:  C Ryan Miller; Christopher P Dunham; Bernd W Scheithauer; Arie Perry
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

4.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

5.  IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.

Authors:  Sumihito Nobusawa; Takuya Watanabe; Paul Kleihues; Hiroko Ohgaki
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

6.  Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.

Authors:  Ahmed Idbaih; Emmanuelle Crinière; Yannick Marie; Audrey Rousseau; Karima Mokhtari; Michèle Kujas; Younas El Houfi; Catherine Carpentier; Sophie Paris; Blandine Boisselier; Florence Laigle-Donadey; Joëlle Thillet; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Neuro Oncol       Date:  2008-06-10       Impact factor: 12.300

7.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

8.  Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

Authors:  Andrey Korshunov; Jochen Meyer; David Capper; Arne Christians; Marc Remke; Hendrik Witt; Stefan Pfister; Andreas von Deimling; Christian Hartmann
Journal:  Acta Neuropathol       Date:  2009-06-19       Impact factor: 17.088

9.  Metabolic enzymes as oncogenes or tumor suppressors.

Authors:  Craig B Thompson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079
View more
  5 in total

1.  Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.

Authors:  Daniel J Brat; Kenneth Aldape; Julia A Bridge; Peter Canoll; Howard Colman; Meera R Hameed; Brent T Harris; Eyas M Hattab; Jason T Huse; Robert B Jenkins; Dolores H Lopez-Terrada; William C McDonald; Fausto J Rodriguez; Lesley H Souter; Carol Colasacco; Nicole E Thomas; Michelle Hawks Yount; Martin J van den Bent; Arie Perry
Journal:  Arch Pathol Lab Med       Date:  2022-05-01       Impact factor: 5.686

2.  Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.

Authors:  Benjamin H Hinrichs; Scott Newman; Christina L Appin; William Dunn; Lee Cooper; Rini Pauly; Jeanne Kowalski; Michael R Rossi; Daniel J Brat
Journal:  Acta Neuropathol Commun       Date:  2016-01-13       Impact factor: 7.801

Review 3.  Molecular Testing of Brain Tumor.

Authors:  Sung-Hye Park; Jaekyung Won; Seong-Ik Kim; Yujin Lee; Chul-Kee Park; Seung-Ki Kim; Seung-Hong Choi
Journal:  J Pathol Transl Med       Date:  2017-05-12

4.  Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.

Authors:  S C Thust; S Hassanein; S Bisdas; J H Rees; H Hyare; J A Maynard; S Brandner; C Tur; H R Jäger; T A Yousry; L Mancini
Journal:  Eur Radiol       Date:  2018-03-23       Impact factor: 5.315

Review 5.  What do we know about IDH1/2 mutations so far, and how do we use it?

Authors:  Craig Horbinski
Journal:  Acta Neuropathol       Date:  2013-03-20       Impact factor: 15.887
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.